Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 249 Days to 305 Days
Enrollment: 1,128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 39
States / cities: Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 817 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more

Conditions: Influenza
Interventions: FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 602 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Fresno, California • Hayward, California • Roseville, California + 2 more

Conditions: SARS-CoV-2 Infection
Interventions: Moderna COVID-19 Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 29 Years
Enrollment: 1,923 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 51
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 45 more

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK134612; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 9 Months to 9 Months
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Birmingham, Alabama • Benton, Arkansas • Little Rock, Arkansas + 15 more

Conditions: Diphtheria, Tetanus
Interventions: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 11 Years to 60 Years
Enrollment: 3,651 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Oakland, California • Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Diphtheria, Pertussis, Tetanus
Interventions: Placebo, Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Durham, North Carolina • Houston, Texas • Seattle, Washington

Conditions: Lymphoma
Interventions: Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Dysentery, Bacillary
Interventions: S.sonnei vaccine, Placebo, S. sonnei 53G challenge strain; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Influenza
Interventions: Influenza Virus Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 11 Months
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 6
States / cities: Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 3 more

Conditions: Influenza
Interventions: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 4,561 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 27 more

Conditions: Healthy
Interventions: Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 525 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Herpes Genitalis
Interventions: VCL-HB01, Phosphate-buffered saline; Biological · Other
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more

Conditions: Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
Interventions: Intismeran autogene, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Bakersfield, California • Los Alamitos, California • Los Angeles, California + 15 more

Conditions: HIV Infections
Interventions: MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more

Conditions: Influenza, Healthy
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 10 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: SARS-CoV-2
Interventions: mRNA-1273; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more

Conditions: Adenocarcinoma of the Prostate
Interventions: Cyclophosphamide, DRibble Vaccine, HPV Vaccinations, Imiquimod; Drug · Biological
Lead sponsor: UbiVac; Industry
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Influenza
Interventions: Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Neoplasms
Interventions: GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab; Drug
Lead sponsor: Seattle Project Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more

Conditions: Influenza Prevention
Interventions: INFLUENZA G1 mHA, Placebo, Al(OH)3; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more

Conditions: Diphtheria, Tetanus, Pertussis
Interventions: DAPTACEL®: DTaP; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 649 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 22
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more

Conditions: Diphtheria, Pertussis, Tetanus
Interventions: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

Pertussis Vaccine in Healthy Pregnant Women

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

H9 Priming Study in Healthy Adults

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®

Tdap Vaccine in Post-Partum Women